Pharmaxis Ltd (PMXSF)
| Previous close | 0.0950 |
| Open | 0.0784 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0784 - 0.0784 |
| 52-week range | 0.0784 - 0.0784 |
| Volume | 400,000 |
| Avg. volume | 0 |
| Market cap | 39.424M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients. In a study of healthy volunteers led by renowned surgeon Prof Fiona Wood AM the Pharmaxis drug demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.
- PR Newswire
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.
- PR Newswire
Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the second of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The increase in dose lead to a predictable increase in drug blood levels in patients and showed the same good tolerability seen in the first dose cohort.
